Akero Therapeutics has shared encouraging preliminary results from a Phase 2b trial assessing the effectiveness and safety of their lead product candidate, efruxifermin. The study focused on patients dealing with…
The pharmaceutical industry's quest to dominate the lucrative market for new obesity medicines may face a formidable challenger in emerging biotech company Structure Therapeutics. According to initial data, Structure's obesity…
Rocket Pharmaceuticals announced on Tuesday that it has reached alignment with the U.S. Food and Drug Administration (FDA) regarding a trial for its cutting-edge treatment for Danon disease. This significant…